{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE292nnn/GSE292716/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Genomics"],"species":["Homo sapiens"],"gds_type":["Genome binding/occupancy profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292716"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"Super-enhancers-driven SOX4/SMAD3 enhances AXL signaling via membrane phospholipid remodeling to accelerate leukemia progression [ChIP-seq]","description":"Cancer often involves aberrant epigenetic activation. In CML-BP, super - enhancer - driven SOX4 and SMAD3 form an auto - regulatory axis. They co - regulate epigenome, activate AXL - related pathways, and mediate membrane phospholipid remodeling. Bemcentinib, an AXL inhibitor, can inhibit CML - BP progression. SOX4/SMAD3 are key factors and Bemcentinib a potential therapy.","dates":{"publication":"2026/05/15"},"accession":"GSE292716","cross_references":{"GSM":["GSM8864096","GSM8864085","GSM8864097","GSM8864086","GSM8864094","GSM8864095","GSM8864092","GSM8864093","GSM8864090","GSM8864091","GSM8864104","GSM8864102","GSM8864103","GSM8864100","GSM8864089","GSM8864101","GSM8864098","GSM8864087","GSM8864099","GSM8864088"],"GPL":["30209"],"GSE":["292716"],"taxon":["Homo sapiens"],"PMID":["[41721601]"]}}